Alterity Therapeutics Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATHE Nasdaq 2836 alteritytherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alterity Therapeutics Limited

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy - Jun 9th, 2026 5:05 am
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy - May 19th, 2026 5:25 am
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy - May 11th, 2026 5:25 am
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 - May 7th, 2026 5:25 am
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update - Apr 30th, 2026 5:25 am
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy - Apr 27th, 2026 5:25 am
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology - Apr 22nd, 2026 5:25 am
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors - Apr 17th, 2026 5:25 am
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting - Apr 16th, 2026 5:25 am
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy - Apr 15th, 2026 5:25 am
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program - Mar 30th, 2026 5:25 am
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit - Mar 9th, 2026 5:25 am
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor - Mar 4th, 2026 5:25 am
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments - Mar 2nd, 2026 5:25 am
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update - Jan 30th, 2026 5:25 am
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 - Jan 21st, 2026 5:25 am
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference - Nov 12th, 2025 5:25 am
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System - Nov 10th, 2025 5:25 am
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report - Oct 31st, 2025 5:25 am
Alterity Therapeutics Limited's (ASX:ATH) Path To Profitability - Oct 11th, 2025 4:34 pm